M. Craig Shepherd
M. Craig Shepherd joined the Board of Trustees of the American Kidney Fund in May 2014 and serves as a member of the board Finance and Public Support Committees. Mr. Shepherd is Managing Director and Chief Legal Officer of DRI Capital, a life sciences private equity firm with over $3 billion under management through its funds Drug Royalty I, II, II Co-Investment Fund and III. He leads DRI’s business development, legal and strategic planning functions, focusing on the worldwide sourcing, evaluation, acquisition and financing of healthcare royalties. He also serves on the firm’s Investment Committee and as co-chair of its Risk Management Committee.
Prior to joining DRI Capital in 2010, Mr. Shepherd held roles of progressive responsibility at Amgen global headquarters in California and international headquarters in Switzerland. These included Executive Director and Associate General Counsel, with legal responsibility for the U.S. Nephrology Business Unit and Amgen Canada, where he served on the executive committee for both business units; Senior Counsel to Amgen Europe/International, where he worked in health systems across more than 35 country markets; Counsel to Amgen USA, and an intern in Amgen product licensing. He began his legal career with Morgan Lewis LLP in the United States and McCarthy Tétrault in Canada. Licensed to practice law in California and in Ontario, Mr. Shepherd holds an MBA from Harvard University, an LLB from McGill University and a B.A. from the University of Western Ontario. In addition to the AKF board, he serves on the boards of Drug Royalty III GP and Medcan Health Management, the largest executive health clinic business in North America, where he chairs the board Corporate Responsibility Committee.